medmix AG (MEDX) AI Stock Analysis

• Market Cap: CHF356.51M
• Dividend Yield: 4.54%
• Average Volume (3M): 115.75K
• Price to Earnings (P/E): 71.6
• Beta (1Y): 1.06
• Revenue Growth: -2.42%
• EPS Growth: -222.68%
• Country: CH
• Employees: 2,684
• Sector: Healthcare
• Sector Strength: 45
• Industry: Industrial - Machinery
• EPS (TTM): 0.33
• Shares Outstanding: 41,262,370
• 10 Day Avg. Volume: 183,978
• 30 Day Avg. Volume: 115,752
• PEG Ratio: -0.38
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 1.02
• P/FCF Ratio: 13.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF16.00
• Price Target Upside: 87.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.7
• Revenue Forecast (FY): CHF464.37M

• Rating: 56 Neutral
• Price Target: CHF12.00 ▲(40.35% Upside)
• Action: Reiterated Date: 11/26/25
• Date: Action: Reiterated 11/26/25

The overall stock score is primarily influenced by the company's mixed financial performance, with operational challenges and increased leverage being significant concerns. Technical analysis indicates a bearish trend, while valuation is affected by a negative P/E ratio, although the high dividend yield offers some compensation.

Positive Factors

Recurring consumables and installed-base revenue

medmix’s business model includes high-repeat consumables tied to installed dispensing equipment. This creates a durable annuity-like revenue stream as customers repurchase tips and single-use components, supporting steady demand and higher lifetime value per customer once systems are specified.

Negative Factors

Revenue weakness and recent declines

Recent revenue declines indicate demand softness and limit operating leverage. With top-line stagnation, the company faces pressure to grow organically or win large programs to restore scale; prolonged revenue weakness constrains margin recovery and reinvestment capacity.

medmix AG Business Overview & Revenue Model

Company Description

Medmix AG designs, develops, manufactures, and delivers high-precision devices and services for the mixing, application, and injection of liquids in a range of viscosities for the healthcare, consumer, and industrial end markets worldwide. It oper...

Read more

Medmix AG designs, develops, manufactures, and delivers high-precision devices and services for the mixing, application, and injection of liquids in a range of viscosities for the healthcare, consumer, and industrial end markets worldwide. It oper...

How the Company Makes Money

medmix AG generates revenue primarily through the sale of its advanced delivery systems and products across its various sectors. The company's key revenue streams include the manufacturing and distribution of injection systems for pharmaceuticals,...

Read more

medmix AG generates revenue primarily through the sale of its advanced delivery systems and products across its various sectors. The company's key revenue streams include the manufacturing and distribution of injection systems for pharmaceuticals,...

medmix AG Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	448.00M	483.90M	486.60M	477.10M	457.30M
Gross Profit	161.90M	159.70M	157.70M	175.40M	181.20M
EBITDA	79.70M	67.60M	68.40M	68.30M	110.60M
Net Income	6.40M	-7.40M	300.00K	11.60M	44.00M
Balance Sheet
Total Assets	969.30M	954.20M	1.01B	1.11B	974.40M
Cash, Cash Equivalents and Short-Term Investments	113.90M	96.20M	130.60M	316.80M	210.00M
Total Debt	391.90M	323.40M	349.70M	473.50M	320.90M
Total Liabilities	536.50M	507.50M	532.40M	601.10M	440.50M
Stockholders Equity	425.70M	436.40M	465.40M	504.80M	533.90M
Cash Flow
Free Cash Flow	33.30M	38.10M	3.20M	9.00M	55.40M
Operating Cash Flow	67.80M	86.60M	56.10M	47.60M	87.30M
Investing Cash Flow	-40.70M	-51.50M	-80.60M	-57.00M	-3.30M
Financing Cash Flow	-36.30M	-48.60M	-153.80M	116.10M	111.60M

medmix AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MEDX, the sentiment is Negative. The current price of 8.55 is below the 20-day moving average (MA) of 8.88, below the 50-day MA of 10.45, and below the 200-day MA of 10.51, indicating a bearish trend. The MACD of -0.53 indicates Negative momentum. The RSI at 26.31 is Positive, neither overbought nor oversold. The STOCH value of 55.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:MEDX.

medmix AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MIKN	69 Neutral	CHF268.88M	6.02	13.91%	2.43%	-1.94%	6.63%
STGN	61 Neutral	CHF184.28M	30.31	―	3.45%	-1.46%	-115.85%
MEDX	56 Neutral	CHF356.51M	71.61	―	4.54%	-2.42%	-222.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FTON	51 Neutral	CHF130.25M	-13.75	-1.88%	―	-15.70%	-670.93%
RIEN	46 Neutral	CHF405.57M	-2.53	―	7.53%	-28.40%	-117.97%
KOMN	44 Neutral	CHF256.88M	-36.22	―	―	-13.64%	-281.19%

medmix AG Corporate Events